Update on nonapnea sleep disorders

Current Opinion in Pulmonary Medicine

Volumn 6, Issue 6, 2000, Pages 507-511

  Vorona, Robert ^a   Ware, J Catesby ^a  

^a SENTARA NORFOLK GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYBUTYRIC ACID; AMANTADINE; APOMORPHINE; CARBIDOPA PLUS LEVODOPA; FLURAZEPAM; HYPNOTIC AGENT; METHYLPHENIDATE; MODAFINIL; OPIATE; PEMOLINE; PERGOLIDE MESILATE; ROPINIROLE; SEROTONIN UPTAKE INHIBITOR; THALIDOMIDE; TRAMADOL; ZALEPLON;

CIRCADIAN RHYTHM; HUMAN; IMMUNE SYSTEM; INSOMNIA; LIVER FAILURE; LOCUS CERULEUS; NARCOLEPSY; NONHUMAN; NONREM SLEEP; REM SLEEP; RESTLESS LEGS SYNDROME; REVIEW; SIDE EFFECT; SLEEP DISORDER;

EID: 0033771469     PISSN: 10705287     EISSN: None     Source Type: Journal    
DOI: 10.1097/00063198-200011000-00008     Document Type: Review

References (44)

1. The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene
2. Narcolepsy in orexin knockout mice: Molecular genetics of sleep regulation
3. The hypocretins: Hypothalamus-specific peptides with neuroexcitatory activity
4. Hypocretin (orexin) activation and synaptic innervation of the locus coeruleus noradrenergic system
5. Locus coeruleus neurons: Cessation of activity during cataplexy
6. Orexin synthesis and response in the gut
7. Narcolepsy: A key role for hypocretins (orexins)
8. Hypocretin (orexin) deficiency in human narcolepsy
9. Nocturnal sleep and daytime sleepiness in normal subjects with HLA-DQBI*0602
10. Health-related quality of life effects of modafinil for treatment of narcolepsy
11. Sleep practitioners need to be aware of new changes in the labeling of pemoline
12. Pharmacokinetics of gammahydroxybutyrate (GHB) in narcoleptic patients
13. Practice parameters for the treatment of restless legs syndrome and periodic limb movement disorder
14. The treatment of restless legs syndrome and periodic limb movement disorder. An American Academy of Sleep Medicine Review
15. Toward a better definition of restless legs syndrome
16. An overview of levodopa in the management of restless legs syndrome in a dialysis population: Pharmacokinetics, clinical trials, and complications of therapy
17. Iron and the restless legs syndrome
18. Charcot-Marie-Tooth disease type 2 with restless legs syndrome
19. Rheumatologic serologies in secondary restless legs syndrome
20. Prevalence and risk factors of RLS in an elderly population: The MEMO study. Memory and morbidity in Augsburg elderly
21. Arm restlessness in patients with restless legs syndrome
22. A randomized, double-blind placebo-controlled trial of iron in restless legs syndrome
23. Changes in excitability of motor cortical circuitry in primary restless legs syndrome
24. An FDOPA PET study in patients with periodic limb movement disorder and restless legs syndrome
25. Striatal dopaminergic function in restless legs syndrome: 18F-dopa and 11C-raclopride PET studies
26. Positron emission tomographic studies in restless legs syndrome
27. Treatment of restless legs syndrome with tramadol: An open study
28. Nocturnal subcutaneous apomorphine infusion in Parkinson's disease and restless legs syndrome
29. Selective serotonin receptor uptake inhibitors can reduce restless legs symptoms
30. Amantadine is beneficial in restless legs syndrome
31. Stability, precision, and near-24-hour period of the human circadian pacemaker
32. Correlates of sleep and waking in drosophila melanogaster
33. Rest in Drosophila is a sleep-like state
34. Differences in gene expression between sleep and waking as revealed by mRNA differential display
35. Cryptochromes: Blue light receptors for plants and animals
36. Light-independent role of CRY1 and CRY2 in the mammalian circadian clock
37. Molecular clock genes in man and lower animals. Possible implications for circadian abnormalities in depression
38. Behavioral and pharmacological therapies for late-life insomnia: A randomized controlled trial
39. Evaluation of chronic insomnia. An American Academy of Sleep Medicine review
40. Zaleplon pharmacokinetics and absolute bioavailability
41. Lack of residual sedation following middle-of-the-night zaleplon administration in sleep maintenance insomnia
42. Dose-dependent effects of endotoxin on human sleep
43. Thalidomide increases both REM and stage 3-4 sleep in human adults: A preliminary study